Baird served as joint-bookrunner on this offering.
AboutExact Sciences Corporation (“Exact” or the “Company”) (NASDAQ: EXAS) recently completed a follow-on offering of 4,000,000 shares of common stock, at a price of $25.75 per share, generating gross proceeds of $103 million. The Company intends to use the net proceeds from the offering to fund expansion of Cologuard® commercialization activities, to fund product development efforts, and for general corporate and working capital.
Exact is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. The Company is headquartered in Madison, Wisconsin.
For additional information about this transaction, please contact:
- December 2014
- Exact Sciences Corporation
- Target Location
- North America